Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (TAX 327) (2004)

Peer-Reviewed Study · Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators · October 7, 2004

Tannock IF et al., 2004-10-07: TAX 327 randomised 1,006 men with metastatic castration-resistant prostate cancer to docetaxel every 3 weeks, weekly docetaxel, or mitoxantrone, all with prednisone. Three-weekly docetaxel extended median survival by 2.4 months (18.9 vs 16.5; HR 0.76; P=0.009).

The median survival was 16.5 months in the mitoxantrone group, 18.9 months in the group given docetaxel every 3 weeks, and 17.4 months in the group given weekly docetaxel.

Abstract (RESULTS)

Tannock IF et al., 2004-10-07: TAX 327 randomised 1,006 men with metastatic castration-resistant prostate cancer to docetaxel every 3 weeks, weekly docetaxel, or mitoxantrone, all with prednisone. Three-weekly docetaxel extended median survival by 2.4 months (18.9 vs 16.5; HR 0.76; P=0.009). Funder: Aventis (now Sanofi); the paper states 'The study was designed by Dr. Tannock in collaboration with Aventis personnel… The data were collected and maintained by Aventis'. Conflicts: NEJM disclosure forms are referenced but not printed in the article text. Maker: Aventis (Taxotere). Comparator: mitoxantrone plus prednisone (active palliative standard), not placebo. Toxicity: grade 3-4 neutropenia and febrile neutropenia more frequent with docetaxel; two treatment-related septic deaths, one in each of the docetaxel and mitoxantrone arms. Also filed as CHH-22 (claims C2, F2). Study type: randomized trial.